歌礼制药-B(01672)：歌礼脂肪靶向、每月一次注射的小分子THRβ激动剂ASC47 联合司美格鲁肽治疗肥胖症的美国临床研究完成所有受试者给药

智通财经07-15

智通财经APP讯，歌礼制药-B(01672)发布公告，评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性、耐受性以及在第29天的初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究， NCT06972992)已于近期完成所有28例受试者给药。28例受试者入组于两个月内快速完成。ASC47-103研究在美国开展，共设3个队列，受试者接受ASC47单剂量...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551139605?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-15 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551139605","market":"sh","top_or_hot":-1,"title":"歌礼制药-B(01672)：歌礼脂肪靶向、每月一次注射的小分子THRβ激动剂ASC47 联合司美格鲁肽治疗肥胖症的美国临床研究完成所有受试者给药","media":"智通财经","content":"<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性、耐受性以及在第29天的初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究， NCT06972992)已于近期完成所有28例受试者给药。28例受试者入组于两个月内快速完成。ASC47-103研究在美国开展，共设3个队列，受试者接受ASC47单剂量...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1317695.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)：歌礼脂肪靶向、每月一次注射的小分子THRβ激动剂ASC47 联合司美格鲁肽治疗肥胖症的美国临床研究完成所有受试者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)：歌礼脂肪靶向、每月一次注射的小分子THRβ激动剂ASC47 联合司美格鲁肽治疗肥胖症的美国临床研究完成所有受试者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-15 06:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1317695.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性、耐受性以及在第29天的初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究， NCT06972992)已于近期完成所有28例受试者给药。28例受试者入组于两个月内快速完成。ASC47-103研究在美国开展，共设3个队列，受试者接受ASC47单剂量...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1317695.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"THR","symbol_name":"Thermon Group Holdings","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1317695.html","article_id":"2551139605","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551139605","pubTimestamp":1752533899,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，歌礼制药-B 发布公告，评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性、耐受性以及在第29天的初步疗效的随机、双盲、安慰剂对照研究已于近期完成所有28例受试者给药。在头对头比较的DIO小鼠模型中，低剂量ASC47与司美格鲁肽联合用药比司美格鲁肽单药疗法多减重56.7%，且不减肌。预计将于2025年第四季度获得ASC47和司美格鲁肽联合用药研究的顶线数据。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"THR":"Thermon Group Holdings","BK1191":"制药","01477":"欧康维视生物-B","BK1515":"抗疫概念","BK1161":"生物科技","01672":"歌礼制药-B","BK1574":"生物医药B类股","BK4096":"电气部件与设备"},"translate_title":"Ascletis Pharma-B (01672): U.S. clinical study of Ascletis's fat-targeted, once-monthly small molecule THRβ agonist ASC47 combined with semaglutide in the treatment of obesity completed dosing of all subjects","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1,"THR":1},"content_text":"智通财经APP讯，歌礼制药-B(01672)发布公告，评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性、耐受性以及在第29天的初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究， NCT06972992)已于近期完成所有28例受试者给药。28例受试者入组于两个月内快速完成。ASC47-103研究在美国开展，共设3个队列，受试者接受ASC47单剂量递增(10毫克、30毫克和60毫克)或注射等量(volume-matched)安慰剂。各队列受试者还接受四次司美格鲁肽(0.5毫克，每周一次)给药。“ASC47临床入组推进如此之快，凸显了业界对减重新疗法以及联合用药潜在优势的浓厚兴趣。”歌礼制药创始人、董事会主席兼首席执行官吴劲梓博士表示，“该试验正如期稳步推进，预计将于2025年第四季度获得其顶线数据。”ASC47是一款由歌礼自主研发的、脂肪靶向、超长效皮下注射的甲状腺激素受体β(THRβ)选择性小分子激动剂。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。在饮食诱导肥胖(DIO)小鼠模型中，脂肪组织中高药物浓度的ASC47相较于司美格鲁肽(63.5% vs 39.6%, p=0.007)和替尔泊肽(68.0% vs 50.4%, p=0.01)能减少更多脂肪，且差异具有显著性。ASC47单药疗法在Ib期肥胖受试者研究中(NCT06427590)显示出长达40天的半衰期。在头对头比较的DIO小鼠模型中，低剂量ASC47与司美格鲁肽联合用药比司美格鲁肽单药疗法多减重56.7%，且不减肌。预计将于2025年第四季度获得ASC47和司美格鲁肽联合用药研究的顶线数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551139605","isCrawlerRequest":true}